At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli ...
Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli ...
Copyright © 2024 EuroAsia24 News.
EuroAsia24 News is not responsible for the content of external sites.